Navigation Links
Jazz Pharmaceuticals to Announce Second Quarter Financial Results on August 11, 2009
Date:8/10/2009

PALO ALTO, Calif., Aug. 10 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that it will report its second quarter 2009 financial results on Tuesday, August 11, 2009. Jazz Pharmaceuticals will host an investor conference call and live webcast to discuss the results, provide guidance for 2009, and give a company update on August 11, 2009, at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The live webcast and press release may be accessed from the Investors section of the Jazz Pharmaceuticals' website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archived version of the webcast will be available through August 25, 2009.

Investors may participate in the conference call by dialing 1-800-299-6183 in the U.S., or 1-617-801-9713 outside the U.S., and entering passcode 52686933.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information please see www.jazzpharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
2. Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results
3. AspireHR Completes Phase 1 SAP HR Initiative for Shire Pharmaceuticals
4. Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
5. Decision Resources Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals Fostamatinib Disodium
6. MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
7. Transcept Pharmaceuticals to Report Second Quarter 2009 Results
8. Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer
9. DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call
10. Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection
11. Addrenex Pharmaceuticals Announces Licensing Agreement With Dream Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... IN (PRWEB) , ... May 03, 2016 , ... ... benefits advisory organization, announces Benefits Alliance Insurance Services as the latest addition to ... Southern California-based Firm comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. ...
(Date:5/3/2016)... ... May 03, 2016 , ... For the sixth consecutive year, ... Technology (ICT) companies in the annual Branham300 listing. For 23 years, the Branhan300 ... ranked by revenue. , “We are honored to be on the Branham300 ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Dr. Poneh ... on cosmetic dental treatments to both new and existing patients. Cosmetic dentistry allows patients ... for patients who have healthy smiles with some minor or more serious cosmetic flaws. ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... availability of the latest release of DocAve 6 Service Pack (SP) 7, ... organizations migrate to SharePoint 2016 and take advantage of the platform’s latest features ...
(Date:5/3/2016)... , ... May 03, 2016 ... ... of Microsoft secure remote access connectivity solutions, today announced the new SecureAccess ... Microsoft DirectAccess. The new Celestix SecureAccess release will enable organizations to get ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- According to market research "Global Magnetic ... Demand Forecast to 2022 - Industry Insights by Architecture ... High Field, Low to Mid Field, and Ultra High ... Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" P&S ... was valued at $5,351.7 million in 2015, and it ...
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/2/2016)... 2016  Deerfield announced today it led the ... Inc. Graybug Vision is an early stage pharmaceutical ... care for ocular diseases including wet age-related macular ... first developed at Johns Hopkins University and has ... Graybug Vision is developing ophthalmology products ...
Breaking Medicine Technology: